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AbstrAct
Introduction A feature of the pathogenesis of idiopathic 
pulmonary fibrosis (IPF) is the excess accumulation of 
extracellular matrix (ECM) in the lungs. Cleavage of the 
ECM by metalloproteinases (MMPs) generates free-
circulating protein fragments known as neoepitopes. 
The PROFILE study suggested that changes in ECM 
turnover proteins may be of value as markers of disease 
progression in patients with IPF. Nintedanib is an approved 
treatment for IPF that slows disease progression by 
reducing decline in forced vital capacity (FVC).
Methods and analysis The INMARK® trial is evaluating 
the effect of nintedanib on the rates of change of 
biomarkers of ECM turnover in patients with IPF, the 
value of changes in these biomarkers as predictors of 
disease progression and whether nintedanib affects 
the associations between changes in these biomarkers 
and disease progression. Following a screening period, 
347 patients with IPF and FVC ≥80% predicted were 
randomised 1:2 to receive nintedanib 150 mg two times 
a day or placebo for 12 weeks, followed by an open-label 
period in which all patients will receive nintedanib for 40 
weeks. The primary endpoint is the rate of change in C 
reactive protein degraded by MMP-1/8 from baseline to 
week 12.
Ethics and dissemination This trial is being conducted 
in compliance with the protocol, the ethical principles 
detailed in the Declaration of Helsinki and in accordance 
with the International Conference on Harmonisation 
Harmonised Tripartite Guideline for Good Clinical Practice. 
The results of the trial will be presented at national and 
international meetings and published in peer-reviewed 
journals.
trial registration number NCT02788474.
Idiopathic pulmonary fibrosis (IPF) is a 
progressive fibrosing interstitial lung disease 
characterised by decline in lung function and 
worsening dyspnoea.1 The clinical course 
of IPF is variable but its prognosis is poor, 
with data collected prior to the availability 
of antifibrotic drugs suggesting a median 
survival following diagnosis of only 2–3 years.1 
Although a decline in forced vital capacity 
(FVC) is considered evidence of disease 
progression in patients with IPF and is predic-
tive of mortality, the course of disease for an 
individual patient remains unpredictable.2 3 
A number of biomarkers have been investi-
gated as predictors of disease progression in 
cohorts of patients with IPF, including gene 
expression profiles,4 5 serum levels of proteins 
associated with lung epithelial injury and 
tissue remodelling (eg, KL-6, matrix metal-
loproteinase (MMP)-7, surfactant protein D 
(SP-D)),6–10 concentrations of type III procol-
lagen peptide in bronchoalveolar lavage 
fluid,11 the bacterial load in the lungs12 13 
and radiological features on high-resolution 
CT (HRCT) of the chest14–16; however, no 
biomarker can yet be used to predict or assess 
disease progression or to guide management 
in an individual patient. In a statement from 
the American Thoracic Society published in 
2016, defining endpoints that more accu-
rately reflect the degree of fibrogenesis, 
Key messages
 ► Protein fragments associated withextracellular ma-
trix turnover (neoepitopes) may be of value as mark-
ers ofdisease progression in patients with idiopathic 
pulmonary fibrosis (IPF).
 ► Nintedanib is an approved treatment forIPF that 
slows disease progression by reducing decline in 
lung function.
 ► The INMARK study is investigating thevalue of 
changes in neoepitopes as predictors of disease 
progression, andthe effect of nintedanib on the rates 
of change of these biomarkers, inpatients with IPF.
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Table 1 Key eligibility criteria for participation in INMARK®
Key inclusion criteria Key exclusion criteria
Age ≥40 years ALT or AST or total bilirubin 
>1.5 × upper limit of normal 
at screening
Diagnosis of IPF according 
to ATS/ERS/JRS/ALAT 
guidelines (Raghu et al, 20111 
within last 3 years)
FEV1/FVC<0.70 
(prebronchodilator)
Chest HRCT (performed 
within 18 months of 
screening) and surgical lung 
biopsy pattern (if available) 
consistent with a diagnosis 
of IPF, assessed by central 
review
Myocardial infarction within 
6 months or unstable angina 
within 1 month of screening
FVC ≥80% predicted at 
screening
Bleeding risk (eg, requiring 
full-dose therapeutic 
anticoagulation or high-dose 
antiplatelet therapy)
History of a thrombotic 
event within 12 months of 
screening
Treatment with nintedanib, 
pirfenidone, azathioprine, 
cyclophosphamide, 
cyclosporine or any 
investigational drug was not 
permitted within 4 weeks of 
randomisation
ALT, alanine transaminase; AST, aspartate transaminase; FEV1, 
forced expiratory volume in 1 s; FVC, forced vital capacity; HRCT, 
high-resolution CT; IPF, idiopathic pulmonary fibrosis.
matrix turnover and functional consequences of fibrosis 
was identified as a pressing research need.17 
A hallmark of the pathogenesis of IPF is the excess 
accumulation of extracellular matrix (ECM) in the lungs 
and remodelling of the lung architecture. Activation of 
fibroblasts and their differentiation into myofibroblasts 
results in an increase in the synthesis, deposition and 
cross-linking of the ECM.18–20 Degradation of the ECM is 
primarily performed by MMPs21 and generates free-circu-
lating fragments of collagen known as neoepitopes.22 23 
As neoepitopes represent unique end-products of proteo-
lytic cleavage of the ECM, concentrations of specific 
neoepitopes, or changes in these concentrations, may be 
useful markers of disease progression in patients with IPF, 
even if they are not directly involved in its pathogenesis. 
To this end, the prospective, multicentre PROFILE study 
investigated 11 MMP-generated neoepitopes as predic-
tors of disease progression in treatment-naïve patients 
with IPF.24 The trial had a two-stage design, with initial 
analyses conducted in a discovery cohort of 55 patients 
and detailed analyses conducted in a validation cohort 
of 134 patients. In the validation cohort, increased 
concentrations of six neoepitopes (biglycan degraded by 
MMP-2/9 (BGM), collagen 1 degraded by MMP (C1M), 
collagen 3 degraded by ADAMTS-1/4/8 (C3A), collagen 
3 degraded by MMP-9 (C3M), collagen 6 degraded 
by MMP-2/9 (C6M), C reactive protein degraded by 
MMP-1/8 (CRPM)) over 6 months were associated with 
disease progression, defined as absolute decline in FVC 
≥10% predicted or death at month 12. A higher rate of 
increase in six neoepitopes (BGM, C1M, C3M, collagen 
5 degraded by MMP-2/9 (C5M), C6M, CRPM) over 3 
months was associated with worse survival. Mortality was 
significantly greater in patients with increasing concen-
trations of C1M, C5M, C6M and CRPM over 3 months 
(rate >0 ng/mL/month) than in those with stable or 
falling concentrations of these neoepitopes over 3 
months (rate ≤0 ng/mL/month). The strongest associa-
tion was observed with CRPM.24 
Nintedanib is an intracellular inhibitor of tyrosine 
kinase receptors, including the fibroblast growth factor 
receptor, platelet-derived growth factor receptor and 
vascular endothelial growth factor receptor as well as 
non-receptor members of the Src family.25 26 Nintedanib 
has shown antifibrotic activity in several in vitro and 
in vivo models of lung fibrosis.26–28 In lung fibroblasts 
from patients with IPF, nintedanib reduces fibroblast/
myofibroblast proliferation and differentiation, induces 
secretion of MMP-2 and reduces ECM secretion.27 In 
clinical trials, nintedanib slowed disease progression by 
reducing the annual rate of decline in FVC compared 
with placebo,29 30 resulting in its approval in many coun-
tries as a treatment for IPF.
Here we describe the objectives and design of the 
INMARK® trial. The main objectives of this trial are to 
evaluate the effect of nintedanib on the rate of change of 
biomarkers of ECM turnover in patients with IPF, confirm 
the prognostic value of changes in biomarkers of ECM 
turnover for disease progression, and assess whether 
nintedanib affects the association between changes in 
biomarkers of ECM turnover and disease progression.
MEthods And AnAlysIs
Eligibility criteria
Key eligibility criteria are summarised in table 1. Briefly, 
patients aged ≥40 years, with a diagnosis of IPF according 
to ATS/ERS/JRS/ALAT guidelines1 within 3 years, 
chest HRCT and surgical lung biopsy pattern (if avail-
able) consistent with a diagnosis of IPF and FVC ≥80% 
predicted were eligible to participate.
trial design
Following a 2–4-week screening period, 347 patients in 13 
countries were randomised 1:2 to receive nintedanib 150 
mg two times a day or placebo double-blind for 12 weeks, 
followed by an open-label period in which all patients will 
receive nintedanib 150 mg two times a day for 40 weeks, 
with a follow-up visit 4 weeks later (figure 1). Patients who 
prematurely discontinue trial drug are asked to attend all 
visits as planned.
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Figure 1 Design of the INMARK® trial.
dosing
Nintedanib 150 mg two times a day is the recommended 
dose for the treatment of IPF. Dose reductions to 100 mg 
two times a day and treatment interruptions are recom-
mended to manage adverse events, based on similar 
recommendations as were provided in the INPULSIS 
trials.30 After resolution of the adverse event, nintedanib 
can be reintroduced and re-escalated to 150 mg two times 
a day at the discretion of the investigator.
trial endpoints
Trial endpoints are presented in table 2. The primary 
endpoint is the rate of change in serum CRPM (ng/mL/
month) evaluated from baseline to week 12. Whole blood 
samples will be collected at baseline and weeks 4, 8 and 
12. As in the PROFILE study, change in serum CRPM will 
be categorised as stable or falling (≤0 ng/mL/month) or 
rising (>0 ng/mL/month) over 12 weeks. The propor-
tion of patients with disease progression (defined as abso-
lute decline in FVC ≥10% predicted or death) over 52 
weeks is a key secondary endpoint. The rates of change 
in serum C3M and serum C1M from baseline to week 12 
are secondary endpoints.
The annual rate of decline in FVC (mL/year) and 
the annual rate of decline in forced expiratory volume 
in 6 s (mL/year) will also be assessed based on home 
spirometry. Home spirometry devices (SpiroPro) and 
instructions were given to patients at screening. Patients 
are asked to perform home-based spirometry at least 
once a week, but ideally on a daily basis, from screening 
until week 52. In-clinic spirometry will be conducted at 
screening, baseline and weeks 4, 8, 12, 16, 20, 24, 36 and 
52, in accordance with ATS/ERS guidelines.31 In-clinic 
spirometry results will be centrally reviewed.
Further endpoints include change from baseline in 
the St George’s Respiratory Questionnaire (SGRQ) total 
score,32 a measure of health-related quality of life in 
patients with chronic respiratory diseases over 52 weeks, 
change from baseline in the University of California 
San Diego Shortness of Breath Questionnaire (UCSD-
SOBQ)33 over 52 weeks, and time to first acute exacerba-
tion over 52 weeks. Acute exacerbations are defined, as in 
the INPULSIS trials,30 as events meeting all the following 
criteria: unexplained worsening or development of 
dyspnoea within 30 days; new diffuse pulmonary infil-
trates on chest X-ray and/or new HRCT parenchymal 
abnormalities with no pneumothorax or pleural effusion 
(new ground-glass opacities) since last visit; exclusion of 
infection as per routine clinical practice and microbiolog-
ical studies; exclusion of alternative causes as per routine 
clinical practice, including left heart failure, pulmonary 
embolism and any identifiable cause of acute lung injury.
Safety will be assessed via the recording of adverse 
events with onset after the first dose and up to 28 days 
after the last dose of study drug, physical examination, 
weight measurements, 12-lead ECG, vital signs and labo-
ratory parameters. Adverse events will be coded using the 
Medical Dictionary for Regulatory Activities (MedDRA).
Predose plasma concentrations of nintedanib and its 
metabolites (BIBF1202 and BIBF 1202-glucuronide)34 
will be determined at weeks 4, 16 and 52.
statistical analysis
Efficacy and safety analyses will be conducted in patients 
who received ≥1 dose of study medication. Sample size 
calculations were based on two-sided tests (α=0.05) 
to provide 90% power to detect a relative difference 
between groups of 20% on the primary endpoint. Rates 
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Table 2 Endpoints in the INMARK® trial
Primary 
endpoint Rate of change in serum CRPM from baseline to week 12
Key 
secondary 
endpoint
Proportion of patients with absolute decline in FVC ≥10% 
predicted or who died over 52 weeks
Secondary 
endpoints
Rate of change in serum C1M from baseline to week 12
Rate of change in serum C3M from baseline to week 12
Further 
endpoints
Rate of change in serum CRPM from week 12 to week 52
Rate of change in serum C1M from week 12 to week 52
Rate of change in serum C3M from week 12 to week 52
Rate of change in serum BGM from baseline to week 12
Rate of change in serum C3A from baseline to week 12
Rate of change in serum C5M from baseline to week 12
Rate of change in serum C6M from baseline to week 12
Rate of change in serum VICM from baseline to week 12
Rate of change in serum BGM from week 12 to week 52
Rate of change in serum C3A from week 12 to week 52
Rate of change in serum C5M from week 12 to week 52
Rate of change in serum C6M from week 12 to week 52
Rate of change in serum VICM from week 12 to week 52
Proportion of patients with absolute decline in FVC ≥5% 
predicted over 52 weeks
Proportion of patients with absolute decline in FVC ≥10% 
predicted over 52 weeks
Proportion of patients who had absolute decline in FVC ≥5% 
predicted or who died over 52 weeks
Time to decline in FVC ≥5% predicted over 52 weeks
Time to decline in FVC ≥10% predicted over 52 weeks
Time to decline in FVC ≥5% predicted or death over 52 weeks
Time to decline in FVC ≥10% predicted or death over 52 weeks
Annual rate of decline in FVC (mL/year)
Absolute change from baseline in FVC % predicted at week 52
Absolute change from baseline in FVC (mL) at week 52
Relative change from baseline in FVC (% predicted) at week 52
Relative change from baseline in FVC (mL) at week 52
Annual rate of decline in FEV6 (mL/year) based on home 
spirometry
Annual rate of decline in FVC (mL/year) based on home 
spirometry
Time to first acute exacerbation over 52 weeks
Change from baseline in SGRQ total score over 52 weeks
Change from baseline in UCSD-SOBQ over 52 weeks
Predose plasma concentrations of nintedanib and its 
metabolites (BIBF 1202 and BIBF 1202-glucuronide)
All spirometry endpoints are based on clinic assessments unless otherwise stated.
BGM, biglycan degraded by MMP-2/9; CRPM, C reactive protein degraded by 
MMP-1/8; C1M, collagen 1 degraded by MMP; C3A, collagen 3 degraded by 
ADAMTS-1/4/8; C3M, collagen 3 degraded by MMP-9; C5M, collagen 5 degraded 
by MMP-2/9; C6M, collagen 6 degraded by MMP-2/9; FEV6, forced expiratory 
volume in 6 s; FVC, forced vital capacity; MMP, metalloproteinase; SGRQ, St. 
George’s Respiratory Questionnaire; UCSD-SOBQ, University of California San Diego 
Shortness of Breath Questionnaire; VICM, citrullinated vimentin degraded by MMP-
2/8.
of change in serum CRPM, C3M and C1M from baseline 
to week 12 will be analysed using a random coefficient 
regression model (with random slopes and intercepts) 
including baseline CRPM, treatment, sex, age and height 
as covariates. Missing data will not be imputed.
The proportion of patients with disease progression 
over 52 weeks will be analysed using logistic regression 
models. First, to confirm the prognostic value of changes 
in biomarkers of ECM turnover for disease progression, 
a logistic regression analysis including baseline CRPM 
and the rate of change in serum CRPM from baseline to 
week 12 as covariates will be assessed in placebo-treated 
patients only. Second, to assess whether nintedanib 
affects the association between changes in biomarkers 
of ECM turnover and disease progression, a logistic 
regression analysis including baseline CRPM, the rate of 
change in serum CRPM from baseline to week 12, treat-
ment and treatment CRPM slope interaction as covari-
ates will be applied. Third, to assess whether nintedanib 
affects disease progression, a logistic regression analysis 
including baseline CRPM, rate of change in serum CRPM 
from baseline to week 12 and treatment as covariates will 
be applied.
Changes in SGRQ and UCSD-SOBQ over 52 weeks will 
be analysed using a mixed model for repeated measures, 
with treatment and visit as fixed effects, baseline total 
score as a covariate and treatment-by-visit and baseline-by-
visit as interaction terms. Safety data will be descriptive.
EthIcs And dIssEMInAtIon
The INMARK® trial is being conducted in compliance 
with the protocol, the ethical principles laid down in 
the Declaration of Helsinki and in accordance with the 
International Conference on Harmonisation Harmo-
nised Tripartite Guideline for Good Clinical Practice. All 
patients provided written informed consent prior to trial 
entry. The trial has been registered with  ClinicalTrials. gov 
(NCT02788474; EudraCT 2015-003148-38). The results 
of the trial will be presented at national and international 
meetings and published in peer-reviewed journals.
dIscussIon
The INMARK® trial aims to illuminate the effects of 
nintedanib on changes in biomarkers of ECM turnover 
in patients with IPF and confirm the prognostic value of 
these biomarkers for disease progression. Validation of 
early markers of disease progression in patients with IPF 
has the potential to bring benefits to clinical practice and 
to facilitate shorter proof-of-concept studies for new ther-
apies.
In the PROFILE study, the rate of change in serum 
CRPM over 3 months was predictive of survival in 
patients with IPF over a median follow-up of almost 
2 years.24 The INMARK® trial will evaluate the effect 
of nintedanib on rate of change in serum CRPM over 
essentially the same time period. A 12-week place-
bo-controlled period was considered acceptable given 
that only patients with relatively well preserved lung 
function (FVC ≥80% predicted) at baseline are eligible 
to participate. Although the effect of nintedanib on 
slowing the rate of FVC decline is the same in patients 
with preserved FVC as in those with greater impairment 
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in lung volume,35 36 many do not receive antifibrotic 
treatment in clinical practice. Following the 12-week 
placebo-controlled treatment period, all patients will 
receive open-label nintedanib, enabling assessment of 
disease behaviour for up to 52 weeks and providing 
data on the impact of a 3-month delay in initiation 
of therapy on outcomes. A further objective of the 
INMARK® trial is to assess the association between 
changes in biomarkers of ECM turnover over 12 weeks 
and disease progression in placebo-treated patients, to 
confirm the results of the PROFILE study. A 1:2 rando-
misation ratio of nintedanib to placebo has been used 
to increase the power to assess this. Disease progression 
has been defined as an absolute decline in FVC ≥10% 
predicted (a degree of decline that has been shown 
to be predictive of mortality in patients with IPF)37 or 
death.
Further analyses of data from the prospective 
PROFILE study identified three serum biomarkers of 
epithelial injury (SP-D, CA19-9, CA-125) that might 
be predictive of disease progression and mortality in 
patients with IPF.10 The INMARK® trial provides an 
opportunity to undertake exploratory assessments of a 
range of alternative biomarkers related to fibrogenesis, 
tissue remodelling and inflammation, including KL-6, 
SP-D, CRP and interleukin-8 as well as gene expression 
analyses.
In the INMARK® trial, FVC will be assessed via 
home spirometry as well as regular in-clinic spirom-
etry, enabling comparison of values obtained in the 
clinic with home measurements taken more frequently. 
Home spirometry may allow a more sensitive estimate 
of FVC decline, as more frequent assessment may result 
in greater accuracy in calculating the slope. In addi-
tion, more frequent measurement of FVC at home 
may enable early detection of rapidly declining FVC, 
thereby enabling early identification of patients with 
disease progression or an acute exacerbation.38 In 
two small studies conducted to examine the feasibility 
and reliability of using home spirometry in patients 
with IPF, FVC values obtained using home spirometry 
showed excellent correlation with readings taken in the 
clinic.38 39 
In conclusion, the results of the INMARK® trial will 
provide insights into associations between changes in 
biomarkers of ECM turnover and disease progression 
and whether treatment with nintedanib affects the rate 
of change in such biomarkers, in patients with IPF and 
limited FVC impairment. These insights might aid the 
prediction of disease progression in individuals with 
IPF.
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